Loading...

PE/Cyanine7 anti-mouse CD62L Antibody

Pricing & Availability
Clone
MEL-14 (See other available formats)
Regulatory Status
RUO
Other Names
L-selectin, LECAM-1, Ly-22, LAM-1, MEL-14
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
MEL-14_PECy7_090707
C57BL/6 mouse splenocytes were stained with CD62L (clone MEL-14) PE/Cyanine7 (filled histogram) or rat IgG2a PE/Cyanine7 isotype control (open histogram).
  • MEL-14_PECy7_090707
    C57BL/6 mouse splenocytes were stained with CD62L (clone MEL-14) PE/Cyanine7 (filled histogram) or rat IgG2a PE/Cyanine7 isotype control (open histogram).
See PE/Cyanine7 spectral data
Cat # Size Price Save
104417 25 µg ¥15,670
104418 100 µg ¥38,270
Description

CD62L is a 74-95 kD glycoprotein also known as L-selectin, LECAM-1, Ly-22, LAM-1, and MEL-14. It is a member of the selectin family and is expressed on the majority of B and naïve T cells, a subset of memory T cells, monocytes, granulocytes, most thymocytes, and a subset of NK cells. CD62L is important in lymphocyte homing to high endothelial venules (HEV) in peripheral lymph nodes and leukocyte "rolling" on activated endothelium. CD62L also contributes to neutrophil emigration at inflammatory sites. CD62L is rapidly shed from lymphocytes and neutrophils upon cellular activation and the expression levels of CD62L (in conjunction with other markers) have been used to distinguish naïve, effector, and memory T cells. CD62L has been reported to interact with CD34, GlyCAM-1, and MAdCAM-1.

Product Details
Technical data sheet

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
C3H/eb mouse B lymphoma 38C-13
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1-3, complement-dependent cytotoxicity4, in vivo and in vitro blocking of adhesion1-3,5, and immunohistochemical staining of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections6. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 104457-104462).

Additional Product Notes
BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Gallatin WM, et al. 1983. Nature 304:30. (IP, Block)
  2. Siegelman MH, et al. 1990. Cell 61:611. (IP, Block)
  3. Lewinsohn DM, et al. 1987. J. Immunol. 138:4313. (IP, Block)
  4. Iwabuchi K, et al. 1991. Immunobiology 182:161. (CMCD)
  5. Pizcueta P, et al. 1994. Am. J. Pathol. 145:461.
  6. Reichert RA, et al. 1986. J. Immunol. 136:3535. (IHC, FC)
  7. Olver S, et al. 2006. Cancer Res. 66:571.
  8. Fukushima A, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:657. PubMed
  9. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719. (FC) PubMed
  10. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed
  11. Lee JW, et al. 2006. Nature Immunol. 8:181.
  12. Shigeta A, et al. 2008. Blood 112:4915 (FC) PubMed
  13. de Vries VC, et al. 2009. Am. J. Transplant. 9:2270 PubMed
Product Citations
  1. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  2. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  3. Robinett RA et al. 2018. Cell systems. 7(1):41-48 . PubMed
  4. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  5. Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed
  6. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  7. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  8. Niven J, et al. 2019. Cell Rep. 28:21. PubMed
  9. Oh–Hora M, et al. 2019. J Immunol. 202:2616. PubMed
  10. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  11. Masiuk KE, et al. 2019. Cell Stem Cell. 24:309. PubMed
  12. Motwani MP, et al. 2018. JCI Insight. 3:e94463. PubMed
  13. Bhatt K, et al. 2018. mSphere. 3:e00352. PubMed
  14. Mohammed RN, et al. 2019. Sci Rep. 4.185416667. PubMed
  15. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  16. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  17. Kretschmer L, et al. 2020. Nat Commun. 0.536805556. PubMed
  18. Horkova V, et al. 2020. Cell Reports. 30(5):1504-1514.e7.. PubMed
  19. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  20. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  21. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  22. Pham D, et al. 2019. Cell Rep. 29:1203. PubMed
  23. Kinder JM, et al. 2020. Cell Reports. 31(12):107784.. PubMed
  24. Zhang H, et al. 2020. Cancer Cell. 37(1):37-54.e9.. PubMed
  25. Fernandes RA, et al. 2020. eLife. 9:e58463.. PubMed
  26. Morris AB, et al. 2020. Immunity. 52(1):136-150.e6.. PubMed
  27. Wu J, et al. 2020. Cell Reports. 31(1):107484. PubMed
  28. Gordan S, et al. 2020. Cell Reports. 29(10):3033-3046.e4.. PubMed
  29. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
  30. Hirose M, et al. 2011. Biochem Biophys Res Commun. 414:437. PubMed
  31. Seeling M, et al. 2013. Proc Natl Acad Sci U S A. 110:10729. PubMed
  32. Stenström M, et al. 2010. Int Immunopharmacol. 10:837. PubMed
  33. Huang W, et al. 2014. J Immunol. 193:2267. PubMed
  34. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  35. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  36. Ibrahim M, et al. 2016. J Evid Based Complementary Altern Med. 21: 171 - 176. PubMed
  37. Li B, et al. 2015. Sci Rep. 5: 14793. PubMed
  38. Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed
  39. Geiger R, et al. 2016. Cell. 167:829-842. PubMed
  40. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  41. BJ L, et al. 2017. J Exp Med . 10.1084/jem.20161461. PubMed
  42. Nguyen T, et al. 2017. Clin Transl Immunology. 10.1038/cti.2017.4. PubMed
  43. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  44. Barsoumian HB, et al. 2020. J Immunother Cancer. 8:00. PubMed
  45. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  46. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  47. Corbett KS, et al. 2020. Nature. 586:567. PubMed
  48. Danzer H, et al. 2020. Elife. 9:00. PubMed
  49. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  50. Kitamoto S, et al. 2020. Cell. 182(2):447-462.e14. PubMed
  51. Hamaidi I, et al. 2020. Cell Metabolism. 32(3):420-436.e12. PubMed
  52. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  53. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  54. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  55. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  56. Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed
  57. DiPiazza AT, et al. 2021. Immunity. 54(8):1869-1882.e6. PubMed
  58. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  59. Kohn M, et al. 2021. Front Immunol. 626627:12. PubMed
  60. Gordon RA, et al. 2020. PLoS One. 15:e0226396. PubMed
  61. Canton J, et al. 2021. Nat Immunol. 22:140. PubMed
  62. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  63. Gonzalez MM, et al. 2021. J Clin Invest. 131:. PubMed
  64. Werner A, et al. 2021. iScience. 24:103076. PubMed
  65. Li G, et al. 2021. Front Oncol. 11:734593. PubMed
  66. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  67. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  68. Hu Y, et al. 2021. J Nanobiotechnology. 19:416. PubMed
  69. Gerber AN, et al. 2021. Cell Rep. 37:109816. PubMed
  70. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  71. Severance AL, et al. 2022. iScience. 25:104400. PubMed
  72. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  73. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  74. Li J, et al. 2021. Cell Rep. 37:110124. PubMed
  75. He X, et al. 2021. Small. 17:e2007165. PubMed
  76. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  77. Ye ZW, et al. 2022. Cell Mol Immunol. 19:588. PubMed
  78. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  79. Hu Y, et al. 2022. J Nanobiotechnology. 20:417. PubMed
  80. Bruggemann TR, et al. 2022. iScience. 25:105185. PubMed
  81. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  82. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  83. Broadfield LA, et al. 2022. Mol Metab. 61:101498. PubMed
  84. Yue Y, et al. 2022. Nat Biomed Eng. 6:898. PubMed
  85. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  86. Weng S, et al. 2022. Front Immunol. 13:1025931. PubMed
  87. Cheng H, et al. 2023. Nat Metab. 5:314. PubMed
  88. Sun Y, et al. 2023. Cell Mol Life Sci. 80:63. PubMed
  89. Jiang L, et al. 2021. Nano Today. 36:. PubMed
  90. De Giovanni M, et al. 2022. Cell. 185:815. PubMed
  91. Hu Y, et al. 2022. Front Immunol. 13:1022011. PubMed
  92. Barsheshet Y, et al. 2022. Int J Mol Sci. 23:. PubMed
  93. Wilson NG, et al. 2023. iScience. 26:105991. PubMed
  94. Falahat R, et al. 2023. Nat Commun. 14:1573. PubMed
  95. Ito M, et al. 2023. Sci Rep. 13:5939. PubMed
  96. Corria-Osorio J, et al. 2023. Nat Immunol. 24:869. PubMed
  97. van Os BW, et al. 2023. Front Cardiovasc Med. 10:1171764. PubMed
  98. Park HJ, et al. 2023. NPJ Vaccines. 8:84. PubMed
  99. Hu Y, et al. 2023. JCI Insight. 8:. PubMed
RRID
AB_313102 (BioLegend Cat. No. 104417)
AB_313103 (BioLegend Cat. No. 104418)

Antigen Details

Structure
Selectin, 95 kD (neutrophils) or 74 kD (lymphocytes)
Distribution

Subsets of B and T cells, monocytes, granulocytes, subset of NK cells

Function
Lymphocyte homing to HEV, rolling on activated endothelium
Ligand/Receptor
CD34, GlyCAM-1, MAdCAM-1
Cell Type
B cells, Granulocytes, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Kishimoto TK, et al. 1990. P. Natl. Acad. Sci. USA 87:2244.
3. Tedder TF, et al. 1995. J. Exp. Med. 181:2259.

Gene ID
20343 View all products for this Gene ID
UniProt
View information about CD62L on UniProt.org
Go To Top Version: 1    Revision Date: 11/30/2012

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account